Malvern-based Recro Pharma has named David Enloe its new president and CEO, writes John George for the Philadelphia Business Journal.

Enloe replaces the company’s founder and longtime CEO, Gerri Henwood, who will now serve as president and CEO of Recro spinout Baudax Bio.

Baudax Bio spun out of Recro late last year and has since received approval from the FDA for its first product, a non-opioid pain medication called Anjeso.

“I am honored to have served as Recro’s president and chief executive officer, and I would like to thank the board and the management team,” said Henwood. “It has been a privilege to work with all of the Recro employees, and I believe we have done tremendous work together, including transforming the business to be a provider of expanded high-value CDMO services.”

Enloe brings to Recro more than two decades of experience in leadership positions at life sciences companies, where he’s worked in biotechnology, clinical drug development, and product manufacturing. His most recent role was as president and CEO of Ajinomoto Bio-Pharma Services, a contract development and manufacturing organization with offices in the U.S., Europe, and Asia.

Read more about Recro Pharma in the Philadelphia Business Journal here.